With one foot already in the healthcare realm, multi-industry manufacturer Jabil is beefing up its biopharma bona fides with a transaction set to propel the company into the CDMO market.

Jabil (JBL) announced the acquisition of Pharmaceutics International, completed February 3. “Jabil is very pleased to announce this acquisition. With our shared commitment to creating the best ...

Jabil, Inc. engages in the provision of manufacturing services and solutions. It operates through the Electronics Manufacturing Services (EMS) and Diversified Manufacturing Services (DMS) segments.

Jabil has acquired contract development and manufacturing organisation (CDMO) Pharmaceutics International (Pii) to offer support for drug development customers. The acquisition of Pii enhances ...

Meanwhile, Jabil’s market share has declined slightly from 5.3% in 2027 to 4.9% in 2024. We noted that Jabil’s revenue in 2024 has experienced the highest decline among competitors ...